Axitinib-related osteonecrosis of the jaw

Vinod Patel*, Chris Sproat, Jerry Kwok, Nikki Tanna

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Tyrosine kinase inhibitors (TKIs) are oral chemotherapy drugs used primarily to treat leukemias, renal cell carcinomas, gastrointestinal stromal tumors, and neuroendocrine tumors. Within this group, a number of drugs have already been implicated in jaw necrosis. Axitinib (Inlyta) is a novel TKI currently licensed for the treatment of renal cell carcinoma. We report the first case, to our knowledge, of jaw necrosis solely related to this medication and review the literature surrounding TKIs and their implication in osteonecrosis of the jaw.

Original languageEnglish
JournalOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics
Early online date18 Aug 2017
DOIs
Publication statusE-pub ahead of print - 18 Aug 2017

Cite this